Bellerophon Therapeutics Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Bellerophon Therapeutics stock.
View analyst ratings for Bellerophon Therapeutics or view top-rated stocks.

Wall Street analysts have given Bellerophon Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Bellerophon Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Bellerophon Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, April 5th 2021.
View our earnings forecast for Bellerophon Therapeutics.

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) issued its quarterly earnings data on Thursday, November, 5th. The biotechnology company reported ($0.84) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by $0.01.
View Bellerophon Therapeutics' earnings history.

Bellerophon Therapeutics' stock was trading at $6.29 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BLPH shares have increased by 0.8% and is now trading at $6.34.
View which stocks have been most impacted by COVID-19.

Bellerophon Therapeutics shares reverse split on the morning of Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 7th 2020. An investor that had 100 shares of Bellerophon Therapeutics stock prior to the reverse split would have 7 shares after the split.

4 Wall Street analysts have issued 12-month price objectives for Bellerophon Therapeutics' shares. Their forecasts range from $19.00 to $35.00. On average, they anticipate Bellerophon Therapeutics' stock price to reach $26.50 in the next year. This suggests a possible upside of 318.0% from the stock's current price.
View analysts' price targets for Bellerophon Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Bellerophon Therapeutics include Tricida (TCDA), Xeris Pharmaceuticals (XERS), CorMedix (CRMD), AVEO Pharmaceuticals (AVEO), Tyme Technologies (TYME), Galecto (GLTO), Cerecor (CERC), ProQR Therapeutics (PRQR), Checkpoint Therapeutics (CKPT), CTI BioPharma (CTIC), Oramed Pharmaceuticals (ORMP), Matinas BioPharma (MTNB), Metacrine (MTCR), Osmotica Pharmaceuticals (OSMT) and Novan (NOVN).
View all of BLPH's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Corbus Pharmaceuticals (CRBP), Novavax (NVAX), Pfizer (PFE), Verastem (VSTM), Gilead Sciences (GILD), OPKO Health (OPK), SCYNEXIS (SCYX) and Dynavax Technologies (DVAX).

(BLPH) raised $60 million in an IPO on Friday, February 13th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and Cowen and Company served as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."

Bellerophon Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.31%), Renaissance Technologies LLC (2.26%), Wells Fargo & Company MN (2.13%), Northern Trust Corp (0.94%), GSA Capital Partners LLP (0.63%) and JPMorgan Chase & Co. (0.11%). Company insiders that own Bellerophon Therapeutics stock include Associates Iv L P Venrock, Fabian Tenenbaum, Jonathan M Peacock, Theodore T Wang and Wassim Fares.
View institutional ownership trends for Bellerophon Therapeutics.

BLPH stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Northern Trust Corp.
View insider buying and selling activity for Bellerophon Therapeutics or view top insider-selling stocks.

BLPH stock was bought by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, GSA Capital Partners LLP, BlackRock Inc., LPL Financial LLC, and JPMorgan Chase & Co.. Company insiders that have bought Bellerophon Therapeutics stock in the last two years include Fabian Tenenbaum, Jonathan M Peacock, Theodore T Wang, and Wassim Fares.
View insider buying and selling activity for Bellerophon Therapeutics or or view top insider-buying stocks.

Shares of BLPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BLPH stock can currently be purchased for approximately $6.34.

Bellerophon Therapeutics has a market capitalization of $60.22 million. The biotechnology company earns $-13,270,000.00 in net income (profit) each year or ($2.95) on an earnings per share basis.

Bellerophon Therapeutics employs 18 workers across the globe.

The official website for Bellerophon Therapeutics is www.bellerophon.com.

Bellerophon Therapeutics is headquartered at 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059.

Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The biotechnology company can be reached via phone at 908-574-4770 or via email at [email protected]